Complement C1s Inhibitors for Complement-Mediated Disorders

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a medical need to inhibit the complement system in patients to treat disorders mediated by dysfunction of the complement system, particularly those associated with the classical complement pathway, alternative complement cascade pathway, and lectin pathway.

Innovation Solution

The use of specific pharmaceutical compounds, including those of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, or XX, or their pharmaceutically acceptable salts, prodrugs, N-oxides, or isolated isomers, to inhibit complement C1s and treat disorders mediated by the complement system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If the complement system is inhibited to treat disorders, then complement-mediated diseases are treated, but immune response may be compromised

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidimmune response compromise

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by selectively inhibiting complement C1s through compounds that target specific complement pathways (classical, alternative, lectin) while preserving other immune functions. The inhibition is localized to complement activation rather than broad immune suppression, allowing treatment of complement-mediated disorders while maintaining overall immune response capability.

Inventive Principle:

Principle #3Local quality

2Reliability

If complement C1s are inhibited, then classical complement pathway is blocked, but other complement pathways may remain active

Engineering Contradiction:

Improvepathway-specific inhibitionVSAvoidcomplement pathway coverage

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent achieves universality by developing compounds that inhibit complement C1s across multiple complement pathways (classical, alternative, and lectin pathways). The same class of compounds provides broad-spectrum complement inhibition, making the treatment versatile for various complement-mediated disorders while maintaining consistent mechanism of action.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250171423A1Pharmaceutical compounds for the treatment of complement mediated disorders

Publication Date: 2025.05.29 ACHILLION PHARMA INC

AI summary

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement C1-mediated disorders.